We present a nonparametric estimator of genotype-specific age-at-onset distributions from kin-cohort data. Standard error calculations are derived and the methodology is illustrated through an analysis of the influence of mutations of the Parkin gene on Parkinson's disease. Semiparametric efficiency considerations are briefly discussed.
INTRODUCTION
When an association between a disease and a genotype at a particular genetic locus is found, it may be of interest to estimate the genotype-specific age-at-onset distributions and to compare the distributions between genotypes.
However, it may be that the genotypes of greatest interest are rare mutations. When a particular genotype is rare, population-based cohort studies may result in too few carriers to allow for accurate estimation of the age-at-onset distribution associated with that genotype. Prevalence case-control studies can enrich the sample with carriers, but with such designs the genotype-specific distributions are generally not completely identifiable.
ESTIMATION
Let I denote the event that the probands are ascertained and their relatives are included in a kin-cohort study sample. Let n denote the number of relatives in the sample, and let i index these relatives. Let p denote the number of possible genotypes, and let j index the genotypes. Let G denote the genotype information available in the sample of probands, and let π ij denote the conditional probability, given G, that the ith study subject is carrying the j th genotype. Let π i denote the p-vector whose j th component is π ij . The π i are calculated using the laws of Mendelian inheritance and, when necessary, estimates of population genotype frequencies. The calculation of π i is discussed in some detail in the illustrative data analysis in §3, and an example of π i is listed in Table 1 .
Let T i denote the the ith subject's age-at-onset, and let N i (s) denote the indicator that T i is less than or equal to s. Let C i denote the observed age of the ith subject at the time of ascertainment, and let C denote the entire collection of censoring times. Let R i (s) denote the indicator that C i is greater than s. It is assumed that the T i are conditionally independent of I and C, given G; three sufficient conditions for this assumption and sampling schemes that satisfy these conditions are discussed in §4. Let F j denote the distribution function of age-at-onset among carriers of the j th genotype, and let F denote the corresponding vector of conditional distribution functions. Finally, let G i denote the conditional distribution of T i given the available genotype information in the probands:
The subject-specific distributions G i are linear combinations of components of F . If the number of distinct π i , and thus the number of distinct G i , is the same as the number of genotypes, and the distinct π i are linearly independent, then the components of F may be written as unique linear combinations of the distinct G i . In this case, the genotype-specific distributions can be unbiasedly estimated as linear combinations of the subject-specific empirical distribution functions computed separately in each of the subsets of relatives corresponding to the distinct π i ; see Table 1 . When there is not a unique linear transformation, then any generalized inverse of the mapping that takes the G i to F may be applied to the degenerate subject-specific empirical distribution functions to obtain unbiased estimators of F . However, with censored age-at-onset data, these subject-specific empirical distribution functions are not available.
In order to motivate the approach taken with censored data, it is useful to view linear combinations of estimators of the G i as integrals of linear combinations of the empirical estimators of dG i . Although censored subjects cannot contribute to empirical estimators of dG i (s) for s exceeding C i , as long as there is sufficient variability in the π i among those subjects with censoring times exceeding s that the map dG i (s) = π T i dF (s), when restricted to those subjects, is invertible, then dF (s) may be estimated by linear combinations of estimators of dG i restricted to the subjects with censoring times exceeding s; natural estimators of dG i (s) for relatives with C i > s are given by dN i (s). The estimators of dG i may then be integrated to obtain estimators of F .
Although there is generally an infinite set of linear combinations of the degenerate estimators of dG i (s) among subjects with C i > s that provide unbiased estimators for dF (s), each corresponding to a generalized inverse, there is a linear combination that is particularly convenient: 
A computational formula for the resulting estimator iŝ
The condition for the existence of the estimator is that the matrix i π i R i (s)π T i be invertible for s ∈ (0, t). This invertibility is equivalent to the invertibility of the mapping
When there is not sufficient variability in π i for subjects with
To show that the estimator is unbiased, note that
Here the second equality follows from the definition of dF (s), and the third follows from the definition of R i (s). The fourth equality follows because π i and R i (s) are in the σ -algebra generated by C and G, and the fifth because of the assumption that the relatives' age-at-onset, T i , are conditionally independent of the ascertainment of the probands and the inclusion of their relatives, I, and the ascertainment times, C, given the available genotype information in the probands, G. The sixth equality follows from the relationship dG i (s) = π
T i dF (s), and the last from the definition of M(s).
The asymptotic normality of √ n{F (t) − F (t)} is discussed in Appendix 1. We now consider estimation of the covariance matrix. Since
it follows thatF (t) − F (t) may be expressed as a sum of zero-mean subject-specific terms, 
which suggests estimating the covariance matrix bŷ
where
The estimator (4) is appropriate when there is only one relative from each family. When there are multiple members from each family, the corresponding estimator would be
Here k indexes family and indexes subjects within a family.
DATA ANALYSIS
Parkinson's disease is a neurodegenerative disorder affecting approximately one to two percent of the population aged 65 or older. Mutations in several genes have been identified in Parkinson's patients; see Polymeropoulos et al. (1997) , Kitada et al. (1998) , Leroy et al. (1998) , Valente et al. (2004) and Paisan-Ruiz et al. (2004) . Among these genes, the Parkin gene is emerging as relatively important. The frequency of mutations in the Parkin gene is estimated to be 50% in familial early-onset Parkinson's patients and 18% in sporadic Parkinson's patients (Lucking et al., 2000) . In late-onset Parkinson's patients the frequency of mutations in the Parkin gene is estimated at 2% (Oliveira et al., 2003) . Although Parkin mutations appear to be associated with both early-and late-onset Parkinson's, the effect of the Parkin gene on age-at-onset of Parkinson's is unknown.
A kin-cohort design to study the association between Parkin mutations and Parkinson's disease symptoms was conducted at Columbia University Medical Center (Marder et al., 2003a) . Altogether 487 probands with Parkinson's disease (cases) and 409 probands without disease (controls) were recruited. Recruitment of the probands was carried out without knowledge of the family history of the disease; this independence of the recruitment of the probands and the family history of Parkinson's in the relatives corresponds to the assumption that T i is conditionally independent of I and C, given G, used in (2).
The probands were then interviewed either face-to-face or over the telephone for ascertainment of Parkinson's and other neurological disease in their first-degree relatives. To ensure the validity of the interview, the family history interviews were also administered to a second person, preferably the first-degree relative himself or herself when possible. An algorithm was created to generate a final diagnosis for each first-degree relative based on all possible interview information; see Marder et al. (2003b) .
There were 224 early-onset, i.e. age-at-onset less than or equal to 50, case probands and 105 control probands analysed for Parkin mutations by sequence analysis and semiquantitative multiplex polymerase chain reaction. An analysis of a subset of 101 cases and 105 controls was previously reported (Clark et al., 2006) . Twenty-seven Parkinson's probands were found to carry mutations, among whom nine carried homozygous or compound heterozygous mutations. None of the control probands carried a mutation. There were 1976 first-degree relatives of the probands included in the analysis, including 634 parents, 734 siblings and 608 children. None of the relatives was genotyped.
The population prevalence of Parkin mutations is unknown, but may be estimated to be 0·004% as described in Appendix 2. In the calculation the rate of mutations in disease-free subjects was taken to be zero. If the upper bound of 0·028 as estimated in Clark et al. (2006) is used instead, the estimate of the population frequency becomes 0·03. Both values were used in the analyses to examine the sensitivity of the method to the misspecification of mutation frequency.
It would be desirable to estimate the distribution of age-at-onset separately in homozygous carriers and heterozygous carriers. However, because of the low population frequency of Parkin mutations, only very few of the relatives are expected to be homozygous carriers. The homozygous and the heterozygous carriers were combined into a single group in the analysis described here.
The conditional probabilities that the relative of a proband carries one or more copies of a mutation, given the proband's genotype status, can be calculated using the Mendelian law and estimated Parkin mutation frequency. These results are summarized in Table 1 .
The estimated conditional distributions of age-at-onset for Parkinson's disease, given a subject carrying one or more copies of mutation, versus the corresponding distribution, given a subject carrying no mutation, and standard errors of the estimates are recorded in Table 2 .
Note thatF (t), the integral of the estimator (1), is not monotone. This reflects the small number of failures times available in the dataset. We applied the pooled-adjacent-violators algorithm (Barlow et al., 1972, Ch. 2 ) to provide a monotone version; see Table 3 and Fig. 1 .
The sample contained 27 relatives who developed Parkinson's disease, among whom four were relatives of Parkin-carrier probands. The cumulative incidence of Parkinson's disease by age 70 increased to 6·1%, with 95% confidence interval (1·0%, 18·6%) for carriers and to 1·0%, with 95% confidence interval (0·5%, 2·3%) for noncarriers. The distribution 0·013  0·000  0·000  30  0·027  0·019  0·000  0·000  35  0·027  0·019  0·000  0·000  40  0·027  0·019  0·001  0·001  45  0·013  0·014  0·002  0·001  50  0·013  0·014  0·002  0·001  55  0·000  0·001  0·004  0·002  60  0·000  0·001  0·008  0·003  65  0·023  0·026  0·009  0·003  70  0·061  0·045  0·010 of age-at-onset up to age 70 in noncarriers is very similar to the distribution in the general population (Marder et al., 2003a ). However, it should be noted that the shape of the distribution of the carriers is largely determined by the four subjects who were relatives of Parkin carrier probands and developed disease at the ages of 25, 29, 63 and 70. To test for a difference between the distributions of age-at-onset in Parkin carriers and noncarriers, at a specific value t, one can refer
to critical values of the standard normal distribution.
For t = 25, 50 and 70, the estimates (standard errors) ofF 1 (t) −F 2 (t) are 0·013(0·013), 0·011(0·014) and 0·051(0·045), giving p-values for the normalized test statistic of 0·32, 0·43 and 0·26. The analysis was carried out again with the Parkin mutation frequency replaced 410 Y. WANG, L. N. CLARK, K. MARDER AND D. RABINOWITZ by 0·03: the results were almost identical, suggesting that the method can be robust against the misspecification of population mutation frequencies.
To examine the relationship between familial aggregation of early-onset Parkinson's disease and Parkin gene mutations, we restricted the analyses to the 1330 relatives of 224 early-onset Parkinson's probands and compared the distribution of the noncarriers estimated from these relatives to that in the population. The Kaplan-Meier method was used to estimate the population distribution of age-at-onset of Parkinson's using the 646 relatives of the 105 control probands and compared it to the distribution of the noncarriers estimated by the proposed method: the cumulative incidence of Parkinson's up to age 70 in the population was estimated to be 1·1% (SE: 0·6%), compared with 1·3% (SE: 0·6%) (p = 0·77) in the noncarrier relatives of early-onset case probands. Various familial aggregation studies reported (Marder et al., 2003a ) that relatives of early-onset cases are at increased risk of being affected with Parkinson's. The current study suggests that increased risk of Parkinson's disease up to age 70 in the relatives of early-onset Parkinson patients could be due to carrying Parkin gene mutations: the relatives of early-onset case probands who do not carry Parkin mutations are not at increased risk of Parkinson's disease compared to the general population up to age 70.
DISCUSSION
The assumption used in (2) to ensure that the approach is unbiased is that the ageat-onset of the relatives are conditionally independent of the inclusion of the probands and ascertainment times in relatives, given probands' genotypes. Three conditions are sufficient for this assumption to hold. The first one is that the age-at-onset in relatives are conditionally independent of the sampling of probands and the inclusion of relatives, given ages at ascertainment of the relatives, probands' genotypes and probands' age-at-onset. The second one is that the age-at-onset in relatives are conditionally independent of age-atonset in probands, given probands' genotypes. The third condition is the usual assumption of conditional independence between failure times and censoring times given covariates, in this case probands' genotypes, in survival regression analyses.
The first condition is satisfied for designs in which the sampling of probands and the inclusion of the relatives in the study dataset are based on the probands' ages-at-onset and possibly genotypes and the ages at ascertainment of their relatives, but not on the relatives' agesat-onset. The method presented here can therefore be used for designs in which probands with certain susceptible genotypes and phenotypes are over-sampled, and relatives with late age at ascertainment to allow for possible manifestation of disease are over-sampled.
The second condition corresponds to the association between age-at-onset in relatives and age-at-onset in probands being explained completely by association between probands' and relatives' genotypes: there is no additional familial risk factor that affects age-at-onset. If there are unmeasured risk factors clustering in the family, relatives of affected probands may exhibit a stronger association between the mutation and disease than individuals in the general population; see Gail et al. (2001) and Begg (2002) . Methods based on random effect models and copula models have been proposed that take into account the residual familial aggregation of additional risk factors; see for example Hsu et al. (2004) and Chatterjee et al. (2006) .
If a family member dies prior to the study, the censoring time may be taken to be the subject's age at death. In this case, the approach developed here would require the death to be independent of the subject's course of the disease.
The approach developed here is not fully efficient. To consider efficiency, it is more convenient to consider estimators of the cumulative hazard rather than the cumulative distribution function. It may be conjectured that an estimator of the form
achieves the semiparametric efficiency bound. The optimal weights M ij for estimating the j th genotype-specific cumulative hazard are defined implicitly by the orthogonality score integral equations for ϕ . The score equations in this situation are
for every x, and
Here the inner product is defined by the expectation,
, and δ x (s) is the Dirac delta function at x.
The optimal estimator may be expressed aŝ
Solving the integral equation corresponds to computing a kind of least squares solution.
Unfortunately there is no explicit solution. For testing the difference of the age-at-onset between genotypes, a weighted version of
can also be used. Computation of standard errors for such a test statistic would rely on the covariance matrix estimator in (5).
Finally, the estimator for the distribution of age-at-onset developed here is not monotone. In some situations, for example in the graphical presentation of the estimator, it may be convenient to obtain a monotone version of the estimator. A pooled-adjacent-violators 412 Y. WANG, L. N. CLARK, K. MARDER AND D. RABINOWITZ algorithm or a convex minorant algorithm may be applied (Groeneboom & Wellner, 1992 
The assumptions of the multivariate central limit theorem applied to the estimator are that there be a positive definite matrix such that
and, for any ε > 0,
where denotes the Euclidean norm. To show (A1), note that the covariance matrix in (A1) is
A law of large numbers argument applied to the convergence of nM(s) to its expectation, for s such that pr(C i > s) > 0, together with a law of large numbers argument applied to the terms
provide the result (A1) for independent and identically distributed C i and π i . To show (A2), first note that (s) . It follows directly that sufficient conditions for √ n{F (t) − F (t)} to be asymptotically normal are that C i and π i be independent and identically distributed, and, for all s ∈ (0, t), pr(C i > s) > 0.
APPENDIX 2
Estimate of the population frequency of Parkin mutations Let A denote the event that a subject carries a Parkin mutation, let B 1 denote the event that the subject has early-onset Parkinson's, let B 2 denote the event that the subject has late-onset Parkinson's, and let B 3 denote the event that the subject does not have Parkinson's. Here pr(A|B 1 ) may be taken as 18% (Lucking et al., 2000) , and pr(A|B 2 ) may be taken as 2% (Oliveira et al., 2003) . Clark et al. (2006) showed that in a sample of 105 disease-free subjects the frequency of Parkin mutation, pr(A|B 3 ), was zero, with the upper 95% confidence bound 0·028. The prevalence rate for Parkinson's is estimated to be 0·1% (Mayeux et al., 1995) , and 10% of Parkinson's cases are estimated to be early onsets, i.e. they develop Parkinson's before the age of 50. Therefore, the prevalence rate of the early-onset Parkinson disease, pr(B 1 ), is about 0·01%, and the population frequency of Parkin mutation can then be estimated as pr(A) = pr(A|B 1 )pr(B 1 ) + pr(A|B 2 )pr(B 2 ) + pr(A|B 3 )pr(B 3 )
= (0·18)(0·01%) + (0·02)(0·09%) + (0)(99·5%)
= 0·004%.
If the upper confidence bound of 0·028 for mutation frequency in disease free subjects is used, the estimate of the population frequency becomes 0·03.
